NEW YORK (GenomeWeb News) — Caprion Pharmaceuticals and Ecopia Biosciences have agreed to merge to form a new company that is focused on drug development, and then sell off Caprion’s proteomics business, the companies said today.
 
The firms said they expect to divest Caprion’s CellCarta proteomics unit within a year, and then will solely pursue oncology and infectious disease therapeutics. The new company will have three clinical therapeutic programs nearing commercialization, the companies said.  
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.